Weill Cornell’s Dr. John Leonard discusses antibody therapy in lymphoma in a Medscape CME program. Click here to view the presentation.
Author: lymphomaprogram
Located on the Upper East Side of New York City, the Lymphoma Program at Weill Cornell Medical College/NewYork Presbyterian Hospital is internationally recognized for our efforts to enable patients with non-Hodgkin lymphoma, Hodgkin disease and related disorders to have the best possible clinical outcome, including cure when possible.
Weill Cornell Among Recipients of $50 Million Stem Cell Research Grant
The Starr Foundation is is making a $50 million gift in support of the Tri-Institutional Stem Cell Initiative (Tri-SCI), which was established through a grant from the Foundation in 2005. The new gift is awarded to the original Tri-SCI members — Weill Cornell Medical College, Memorial Sloan-Kettering Cancer Center, The Rockefeller University. The grant will support and enhance collaborative, pioneering stem cell research at the three adjacent Manhattan campuses. The laboratories are investigating the properties of embryonic stem cells, which have the potential to differentiate into any cell type in the body, and adult stem cells, which are found in various tissues and can give rise to specific cell types. These studies are opening new avenues for understanding a range of health conditions, including developmental disorders, neurodegenerative diseases and cancer.
Click here to read the full press report on the grant.
OncLive: Dr. John Leonard Discusses What’s New in DLBCL Treatment
At the 16th Annual International Congress on Hematologic Malignancies, Dr. John Leonard, the director of the Lymphoma Program at Weill Cornell Medical College, discussed several novel therapies currently under investigation for DLBCL. Today OncLive published an article, “Beyond R-CHOP-21: What’s New in Diffuse Large B-Cell Lymphoma” summarizing Dr. Leonard’s discussion.
“The current standard for patients with advanced diffuse large B-cell lymphoma (DLBCL) is R-CHOP-21 (21-day rituximab-cyclophosphamidedoxorubicin- vincristine-prednisone). However, while this regimen cures approximately two-thirds of patients, a significant fraction of patients will still relapse, and the prognosis for these patients is poor.”
Approaches being evaluated include substituting an alternate chemotherapy regimen for CHOP in combination with rituximab; R-EPOCH (rituximabetoposide- prednisone-vincristine-doxorubicin-cyclophosphamide); and adding a new agent to R-CHOP-21.
Click here to read the full article in in OncLive.
New Developments in Lymphoma 